Referencias bibliográficas

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 Jul;9(7):689-701. [Pubmed]
2. Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN. Review: molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol. 2011 Feb;37(1):94-113. [Pubmed]
3. Søndergaard CB, Nielsen JE, Hansen CK, Christensen H. Hereditary cerebral small vessel disease and stroke. Clin Neurol Neurosurg. 2017 Apr;155:45-57. [Pubmed]
4. Hack RJ, Rutten J, Lesnik Oberstein SAJ. CADASIL. En: Adam MP, Ardinger HH, Pagon RA, et al. (eds.). GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993-2021. Disponible en: [Enlace]
5. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann N Y Acad Sci. 1997 Sep 26;826:213-7. [Pubmed]
6. Dichgans M, Herzog J, Gasser T. NOTCH3 mutation involving three cysteine residues in a family with typical CADASIL. Neurology. 2001 Nov 13;57(9):1714-7. [Pubmed]
7. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000 Mar;105(5):597-605. [Pubmed]
8. Ghosh M, Balbi M, Hellal F, Dichgans M, Lindauer U, Plesnila N. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ann Neurol. 2015 Dec;78(6):887-900. [Pubmed]
9. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004 Nov;127(Pt 11):2533-9. [Pubmed]
10. Amberla K, Wäljas M, Tuominen S, Almkvist O, Pöyhönen M, Tuisku S, et al. Insidious cognitive decline in CADASIL. Stroke. 2004 Jul;35(7):1598-602. [Pubmed]
11. Dichgans M, Wick M, Gasser T. Cerebrospinal fluid findings in CADASIL. Neurology. 1999 Jul 13;53(1):233. [Pubmed]
12. Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001 Dec 15;358(9298):2049-51. [Pubmed]
13. Mehta A, Hughes DA. Fabry Disease. En: Adam MP, Ardinger HH, Pagon RA, et al. (eds.). GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993-2021. Disponible en: [Enlace]
14. Michaud M, Mauhin W, Belmatoug N, Garnotel R, Bedreddine N, Catros F, et al. When and How to Diagnose Fabry Disease in Clinical Pratice. Am J Med Sci. 2020 Dec;360(6):641-9. [Pubmed]
15. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003 Feb 18;138(4):338-46. [Pubmed]
16. Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med. 2016 Dec;18(12):1181-5. [Pubmed]
17. Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al.; FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007 Aug;157(2):331-7. [Pubmed]
18. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007 Feb;91(2):210-4 [Pubmed]
19. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007 May;28(10):1228-35. [Pubmed]
20. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009 Mar;40(3):788-94. [Pubmed]
21. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016 Jan;89(1):44-54. [Pubmed]
22. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018 Apr;123(4):416-27. [Pubmed]
23. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. J Inherit Metab Dis. 2011 Apr;34(2):509-14. [Pubmed]
24. Pereira S, Vieira B, Maio T, Moreira J, Sampaio F. Susac's Syndrome: An Updated Review. Neuroophthalmology. 2020 May 1;44(6):355-60. [Pubmed]
25. Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015 Mar 27;10:36. [Pubmed]
26. Sauma J, Rivera D, Wu A, Donate-Lopez J, Gallego-Pinazo R, Chilov M, et al. Susac's syndrome: an update. Br J Ophthalmol. 2020 Sep;104(9):1190-5. [Pubmed]
27. García-Carrasco M, Mendoza-Pinto C, Cervera R. Diagnosis and classification of Susac syndrome. Autoimmun Rev. 2014 Apr-May;13(4-5):347-50. [Pubmed]
28. Kleffner I, Dörr J, Ringelstein M, Gross CC, Böckenfeld Y, Schwindt W, et al.; European Susac Consortium (EuSaC). Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1287-95. [Pubmed]
29. Rennebohm RM, Asdaghi N, Srivastava S, Gertner E. Guidelines for treatment of Susac syndrome - An update. Int J Stroke. 2020 Jul;15(5):484-94. [Pubmed]